David Dyer, MD
Ophthalmology · Lenexa, KSNPI 1518994631
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 152 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations.
Across 152 payments — averaging $42.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$2K
- Alimera Sciences, Inc.$632
- Genentech USA, Inc.$606
- Novartis$516
- AbbVie$482
- Biotissue Holdings Inc.$463
- plus $2K from 16 others
What the payments were for
- Food & beverage$6,22397%
- Entertainment$1743%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 24 | $1,514 |
| Alimera Sciences, Inc. | 16 | $632 |
| Genentech USA, Inc. | 12 | $606 |
| Novartis | 15 | $516 |
| AbbVie(2 entities) | 21 | $482 |
| Biotissue Holdings Inc. | 4 | $463 |
| ANI Pharmaceuticals, Inc. | 16 | $393 |
| Regeneron Healthcare Solutions, Inc. | 13 | $337 |
| Biogen | 5 | $212 |
| Carl Zeiss Meditec USA, Inc. | 2 | $199 |
| Optos, Inc. | 3 | $174 |
| Alcon | 4 | $164 |
| Mallinckrodt Hospital Products Inc. | 2 | $141 |
| Mallinckrodt Enterprises LLC | 1 | $123 |
| Coherus Oncology, Inc. | 4 | $95 |
| Oculus Surgical Inc. | 1 | $91 |
| Eyepoint US, Inc. | 2 | $83 |
| Sandoz | 2 | $69 |
| Bausch & Lomb Americas Inc. | 2 | $47 |
| Topcon Healthcare Solutions, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $18 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Syfovre$432
- ACTHAR$245
- VABYSMO$240
- Iluvien$212
- Prokera$188
- AmnioGraft$188
- OZURDEX$125
- ARTEVO 800$100
How this compares
$6,398 in reported general payments places this provider in the 85th percentile of 135 ophthalmology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 87 | $2,642 |
| Ofloxacin | 50 | $789 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $488 |
| Latanoprost | 11 | $134 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Lenexa
- Blake CooperLenexa$100K
- Michael EllisLenexa$38K
- Ivan BatlleLenexa$8K
- Daniel FeilerLenexa$4K
- Steven CohenLenexa$4K
- Gregory FoxLenexa$3K
- Ravi SinghLenexa$2K
- Beatty SuiterLenexa$2K
- Nish PatelLenexa$2K
- Daniel DurrieOverland Park$974K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.